| dc.description.abstract | miRNAs reveal irregular expressions in women with pregnancy complications (Bogdanet et al., 2021; Memtsa et al., 2019; Rana et al., 2020). Further research is required to further define an individual miRNA as a biomarker in placental disorders. Checking for disorganized placental and circulatory miRNAs is necessary in large-scale preclinical studies. According to the literature, generally, large-scale clinical trials should be planned to evaluate the clinical significance of circulating miRNAs in pregnancy-related conditions. This is important, since it will help determine their sensitivity and specificity for inclusion in clinical diagnostics and follow-up tests. Considering the multiple factors influencing the growth of pregnancy, it appears likely that a panel of various biomarkers, including genomic, transcriptomic, proteomics, and biophysical ones, combined with maternal characteristics, can be utilized to make better the health care for pregnant women in the future. | tr |
